From Sequence to Patient in Under 12 Months: A Case Study in Advancing Complex Cancer Immunotherapies

Complex biologics such as bifunctional antibodies are opening new therapeutic possibilities in oncology, but these molecules present significant challenges for manufacturing teams. Non-standard architectures can often translate to low expression and difficult developability, making cell line development a critical bottleneck between a promising sequence and a viable clinical candidate.

In this GEN webinar, Joseph Shultz (vice president of technical development and manufacturing, Ottimo Pharma) and Imroz Ghangas (vice president of commercial sales, Asimov) discuss strategies for achieving high-performing clonal titers and advancing a dual-paratopic cancer immunotherapy from sequence to dosed patient in under a year. Attendees will learn about the unique attributes of Ottimo’s molecule and how a specialist partnership with Asimov accelerated the program. The presenters will also introduce the CHO Edge System, which combines Asimov’s proprietary GS knock-out CHO host, hyperactive transposase, library of characterized genetic elements, and AI-driven genetic design tools to routinely deliver clonal titers of 8-12 g/L.

A live Q&A session will follow the presentation offering you a chance to pose questions to our expert panelists.

Produced with support from: